Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLms Capital Regulatory News (LMS)

Share Price Information for Lms Capital (LMS)

Share Price is delayed by 15 minutes
Get Live Data
15.50    0.00 (0.00%)
Bid:
14.10
Ask:
16.90
Spread: 2.80 (19.858%)
Market Cap: £12.51m
LMS Live PriceLast checked at - London Stock Exchange

Intraday Lms Capital Share Chart

Third Quarter 2021 Update

22 Oct 2021 07:00

RNS Number : 8626P
LMS Capital PLC
22 October 2021
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

22 October 2021

 

 

LMS CAPITAL PLC

Third Quarter 2021 Update

 

 

LMS Capital plc (the "Company") the listed Investment Company provides the following update covering the period from 30 June 2021 to date.

 

Financial Highlights

 

· Unaudited Net Asset Value ("NAV") at 30 September 2021 was £46.9 million (58.0p per share). This compares to £47.6 million (59.0p per share) at 30 June 2021;

· Interim dividend of £0.2 million paid in September; and

· Cash at 31 September 2021 was £20.5 million compared to £21.4 million at 30 June 2021

 

Unaudited Net Asset Value at 30 September 2021

 

The £0.7 million decrease in the NAV during the third quarter reflects payment of the interim dividend of £0.2 million and £0.5 million of other movements. The other movements comprise the following:

· Unrealised losses of £0.7 million on the investment portfolio;

· £0.4 million of portfolio and £0.3 million of non-portfolio foreign exchange gains from the strengthening of the U.S. Dollar against sterling; and

· £0.4 million of running costs and £0.1 million of investment related costs.

 

 

 

 

The 30 September 2021 NAV is summarised below:

 

 

Unaudited 

30 September 2021 

 

Unaudited

30 June 2021

 

£ 000s

Quoted Investments

244

285

Unquoted Investments

8,067

7,568

Funds

13,216

13,562

Subtotal Investment portfolio

21,527

21,415

 

 

 

Cash

20,474

21,372

Dacian Investment - Funds Deposited

6,730

6,557

Other Net Assets/Liabilities 

(1,873)

(1,752)

Net Asset Value

46,858

47,592

 

 

The NAV at the end of September is based on the valuation of the Company's investments as at 30 June 2021, adjusted for transactions in the three months ended 30 September 2021, price movements on quoted securities, movements in foreign currency exchange rates, cash calls and distributions from funds, and the latest information available from third party fund managers.

 

Portfolio Unrealised Net Gains

 

The portfolio net unrealised losses of £0.7 million, excluding foreign exchange movements, are summarised below:

 

Quoted Investments

 

The Company's quoted investment valuations decreased by a net £0.1 million during the third quarter of 2021, reflecting underlying market price decreases.

 

Unquoted Investments

 

The Company's unquoted investments include assets managed by San Francisco Equity Partners (ICU Eyewear and YesTo), our direct holdings in Medhost and Elateral and a convertible debt instrument with IDE Group Holdings.

 

Total unquoted investment unrealised losses were £0.1 million. This primarily relates to YesTo where the remaining value of the investment was written off.

Elateral - The Company has increased its investment by £0.4 million as part of an agreement to buyout the former 50% co-investor and provide additional working capital. LMS' ownership has increased from approximately 50% to 62.5% of the economic interest in the company, the balance being held largely by our new operating partner and the Elateral Chairman both of whom have invested alongside LMS. Elateral operates in the digital marketing sector and has a cloud-based software platform which facilitates the creation and customisation of digital and print marketing materials.

 

Funds

 

The Company's fund investments include its holding in Brockton Capital Fund I, Opus Capital Partners, Weber Capital Partners ("Weber") and five other smaller fund interests.

 

Fund unrealised net losses were £0.5 million. The principal movements were:

· YesTo - Unrealised loss of £0.7 million. This investment, held through and managed by San Francisco Equity Partners, has been written down to zero pending the outcome of a review of the financing requirements of the business;

· Brockton Fund 1 - Unrealised gain £0.4 million, reflecting the third quarter movement in the discounted cash flow valuation; and

· Weber - unrealised loss of £0.2 million due to the performance in the U.S. microcap equities held in the fund. Year to date the fund has increased by 17.2%

 

The carrying value of the funds is based on the latest available information from the respective fund managers, generally the 30 June 2021 fund valuation reports except for Weber, which is based on 30 September 2021 valuations.

 

Portfolio Realisations

 

There were no portfolio realisations or fund distributions during the third quarter.

 

Liquidity and Outlook

 

The Company continues to maintain significant cash balances, £20.5 million at 30 September, and remains highly cautious about the way its liquid resources are deployed. The Company continues to review opportunities with its real estate teams and has a pipeline of opportunities for other investments.

 

Dacian

 

Dacian, the Romanian oil and gas production company in which LMS, together with other investors, has committed to invest, has not yet received the necessary approvals in Romania for its first acquisition of a business comprising 40 onshore oil and gas fields.

LMS' and other investors' commitments are conditional on the necessary approvals being obtained. LMS has committed $9.1 million, which comprises $9.1 million of senior loans bearing interest at 14% per annum and a 32% equity ownership in the company.

Notwithstanding some delay due to the impact of Covid-19 and government reorganisations in Romania, the process is taking substantially longer than envisaged at the time the commitment was made.

The Dacian management team believes, based on the evidence available to it, that the approval process is moving towards successful conclusion, although the timing of such conclusion is difficult to predict.

The Board maintains close contact with the Dacian team and continues to monitor the situation closely. If circumstances change the Board will reconsider its position, however at present it remains of the view that the merits of the transaction outweigh the delays, and therefore should await the conclusion of the approval process.

 

The information contained in this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon publication of this announcement, this inside information is now considered to be in the public domain.

 

 

22 October 2021

 

For further information please contact:

LMS Capital PLC

Nick Friedlos, Managing Director

0207 935 3555

 

Shore Capital

Robert Finlay

0207 408 4050

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDMBBITMTITBTB
Date   Source Headline
13th May 20263:32 pmRNSResults of 2026 Annual General Meeting
24th Apr 20263:37 pmRNSTR‑1: Notification of Major Holdings
24th Apr 20267:00 amRNSFirst Quarter 2026 Update
17th Apr 20261:09 pmRNSNotice of Annual General Meeting
19th Mar 20267:00 amRNSFinal Results for the Year Ended 31 December 2025
17th Feb 202612:37 pmRNSTR‑1: Notification of Major Holdings
16th Feb 20267:00 amRNSCompany Update and Unaudited Net Asset Value
13th Jan 20267:00 amRNSSecond Return of Capital
4th Nov 20257:00 amRNS3rd Quarter Trading Update
8th Oct 20259:30 amRNSChange of Auditor
11th Aug 20257:01 amRNSHalf-year Report
11th Aug 20257:00 amRNSInvestment in Dacian
15th Jul 20253:21 pmRNSTotal Voting Rights
8th Jul 20257:00 amRNSStatement re B Share issue
15th May 202510:23 amRNSResult of AGM & GM
14th May 20253:01 pmRNSResult of AGM & GM
14th May 20257:00 amRNSAGM Statement
24th Apr 202510:43 amRNSNotice of GM Broadcast
24th Apr 202510:36 amRNSNotice of GM
22nd Apr 20257:00 amRNS1st Quarter Results
8th Apr 20251:47 pmRNSNotice of AGM Broadcast
8th Apr 20251:34 pmRNSNotice of AGM
28th Mar 20257:00 amRNSFinal Results
17th Mar 20259:07 amRNSHolding(s) in Company
13th Mar 20257:00 amRNSStatement re proposed managed realisation
25th Feb 20251:27 pmRNSHolding(s) in Company
19th Feb 20258:44 amRNSHolding(s) in Company
13th Feb 20257:00 amRNSNet Asset Value(s)
20th Dec 20249:22 amRNSDirector/PDMR Shareholding
13th Nov 20244:32 pmRNSCompany Secretary Change
18th Oct 20247:00 amRNSThird Quarter 2024 Update
5th Sep 20243:49 pmRNSDirector/PDMR Shareholding
31st Jul 20247:00 amRNSSenior Independent Director Appointment
31st Jul 20247:00 amRNSHalf-year Report
15th Jul 20247:00 amRNSUpdate on Investment
16th May 20244:54 pmRNSResult of AGM and Dividend Declaration
15th May 20247:00 amRNSDirectorate Change
8th May 20249:19 amRNS1st Quarter Results
25th Apr 20244:09 pmRNSInvestor Presentation
25th Apr 20243:10 pmRNSHolding(s) in Company
24th Apr 20244:42 pmRNSNotice of AGM
19th Mar 20247:00 amRNS2023 Final Results
8th Mar 20242:23 pmRNSHolding(s) in Company
23rd Feb 20247:00 amRNSNet Asset Value(s)
29th Jan 20247:00 amRNSPortfolio Update - Brockton Fund 1
27th Dec 20237:00 amRNSPortfolio Update
21st Dec 20237:00 amRNSRetirement living investment platform
30th Oct 20237:00 amRNSThird Quarter 2023 Update
16th Aug 20233:11 pmRNSLong Term Incentive Plan Awards
1st Aug 20237:00 amRNSHalf year results for the 6 months ended 30.06.23

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.